mitoxantrone has been researched along with Leukemia in 129 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Flavopiridol given by 1-hour bolus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias." | 9.15 | Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. ( Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M, 2011) |
| "To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia." | 9.10 | Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. ( Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL, 2002) |
| "The present study was undertaken to assess the feasibility, toxicity and antileukemic activity of sequential chemotherapy including mitoxantrone, etoposide, carboplatin and intermediate-dose cytarabine in adult patients with refractory and relapsed acute myelogenous (AML) or lymphoid (ALL) leukemia." | 9.09 | Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. ( Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J, 2000) |
| "A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent." | 9.08 | Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. ( Audhuy, B; Berthou, C; Cahn, JY; Caillot, D; Casassus, P; Colombat, P; Desablens, B; Guyotat, D; Harousseau, JL; Ifrah, N; Lamy, Y; Maloisel, F; Moreau, P; Pignon, B; Sadoun, A; Solary, E; Witz, B, 1996) |
| "BHAC-MMP therapy, a combination of behenoyl-ara-C, mitoxantrone, 6-mercaptopurine and prednisolone, was applied to 49 patients with acute leukemia for remission induction." | 9.06 | [A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Shibata, H; Yasunaga, K; Yonezawa, T, 1986) |
| "Twenty-two patients with relapsed or refractory acute leukemia received 31 treatment courses of mitoxantrone (10 to 12 mg/m2/d) as a one-hour infusion for five days." | 9.06 | A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ( Choi, KE; Daly, KM; Han, DS; Larson, RA; Sinkule, JA, 1987) |
| "A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine." | 9.05 | Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984) |
| "Despite the long-standing and extensive use of mitoxantrone (MTZ) for the treatment of aggressive forms of multiple sclerosis (MS), especially in Europe, its benefit-risk profile remains controversial." | 8.89 | Mitoxantrone-related acute leukemia in MS: an open or closed book? ( Chan, A; Lo-Coco, F, 2013) |
| "The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy." | 8.86 | Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. ( Gronseth, G; Marriott, JJ; Miyasaki, JM; O'Connor, PW, 2010) |
| "Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate." | 8.83 | The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 8.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "To evaluate the incidence of therapy-related acute leukaemia (t-AL) after single-agent mitoxantrone (MITO) treatment, we reviewed medical records of patients in three studies of single-agent MITO therapy for multiple sclerosis (MS) and existing literature on MITO therapy in MS, leukaemia, and solid tumors." | 8.81 | A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. ( Butine, MD; De Goodkin, DE; Edan, G; Eisenmann, S; Ghalie, RG; Gonsette, RE; Hartung, HP; Le Page, E; Mauch, E, 2002) |
| "5 years suggests that the risk of either therapy-related acute leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis is low when patients are treated within standard protocol." | 7.78 | Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012) |
| "Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported." | 7.78 | Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| "Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS)." | 7.76 | [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. ( Ansorge, N; Chan, A; Dührsen, U; Gold, R; Meyer, C; Nückel, H; Ritter, PR; Salmen, S; Schmidt, WE; Siglienti, I; Stroet, A, 2010) |
| "Mitoxantrone (Mx) is used as a second-line treatment in multiple sclerosis." | 7.73 | [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]. ( Baldauf, E; Berger, E; Deconinck, E; Nollet, S; Rumbach, L, 2006) |
| "The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)." | 7.69 | Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994) |
| "Fourteen patients with relapsed or refractory acute leukemia received combination chemotherapy of mitoxantrone 6 mg/m2/day intravenously for three to six days and cytosine arabinoside 60 mg/m2/day intravenously over 24 hours continuously for five to ten days." | 7.68 | [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia]. ( Fujiwara, Y; Murase, T; Ohkita, T; Tanaka, M; Uchida, T; Wakita, A, 1992) |
| "Fifteen adult patients with relapsed or refractory acute leukemia were treated with quinine formiate (30 mg/kg/d in continuous intravenous (IV) infusion from day 1 through day 5 or 6) associated with Ara-C (1 g/m2 in 3-hour IV infusion twice a day for 5 days) and five increasing doses of mitoxantrone (from 8 mg/m2/d for 4 days to 12 mg/m2/d for 5 days)." | 7.68 | Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. ( Caillot, D; Casasnovas, RO; Chauffert, B; Dumas, M; Guy, H; Maynadie, M; Solary, E, 1992) |
| "Forty-six patients with acute leukemia were treated with mitoxantrone as a single agent." | 7.67 | Mitoxantrone in the treatment of acute leukemia. ( Coccia-Portugal, MA; Falkson, G; Terblanche, AP; Vorobiof, DA, 1987) |
| "Thirty cases of acute leukemia in patients over 15 years of age (18 males and 12 females) were treated with combinations containing mitoxantrone between January 1986 and August 1987 at the Kuwait Cancer Control Center." | 7.67 | Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. ( Baker, H; Fayyaz, S; Khalifa, F; Salfiti, R; Samir Motawy, M, 1989) |
| "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy." | 7.67 | Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985) |
| "Mitoxantrone, a new anthracenedione, was administered to twenty-five evaluable patients with relapsed or refractory acute leukemia between January 1982 and September 1984." | 7.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Hattori, M; Kaneko, Y; Kumai, R; Maseki, N; Sakurai, M; Sampi, K, 1985) |
| "Twenty-four patients with acute leukemia and blast crisis of chronic myelocytic leukemia in relapse or refractory to standard chemotherapy were eligible for treatment with mitoxantrone." | 7.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Ho, AD; Meyer, P; Mjaaland, I; Ostendorf, P; Seither, E, 1985) |
| "We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia: an interim report. ( Arlin, ZA; Bertino, J; Cassileth, P; Dukart, G; Gams, R; Moore, J; Reisman, A; Schoch, I; Silver, RA, 1985) |
| "Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone." | 7.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985) |
| "A phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione) was conducted in 35 patients (22 male: 13 female) with acute leukemia." | 7.67 | A phase II study of mitoxantrone in acute leukemia. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1985) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 7.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 7.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "A phase II study of mitoxantrone was conducted on acute leukemia." | 7.67 | [A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1986) |
| "A phase II study of acute leukemia with mitoxantrone (MIT) was conducted by the Tokai Blood Cancer Study Group." | 7.67 | [Phase II study of mitoxantrone in patients with acute leukemia]. ( Hirano, M; Ikeda, Y; Kimura, K; Kobayashi, M; Ohara, K; Ohta, K; Shirakawa, S; Yamada, K; Yoshikawa, H; Yoshikawa, S, 1986) |
| "A total of seventeen patients with acute leukemia were treated with mitoxantrone for induction therapy." | 7.67 | [Phase II study of mitoxantrone for acute leukemia]. ( Hirayama, F; Kanakura, Y; Kubota, Y; Masaoka, T; Nakamura, H; Oguma, S; Shibata, H; Tani, Y; Tatsumi, Y; Ueda, T, 1984) |
| "Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984." | 7.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986) |
| "A multidrug-resistant variant of the human HL-60 promyelocytic leukemia cell line (HL-60/MX2) has been isolated in vitro by subculturing these cells in progressively increasing concentrations of mitoxantrone." | 7.67 | Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. ( Dalton, WS; Harker, WG; Meltzer, PS; Slade, DL; Trent, JM, 1989) |
| "Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)." | 7.66 | Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983) |
| "Mitoxantrone was administered to 41 adults with refractory acute leukemia." | 7.66 | Phase II trial of mitoxantrone in refractory acute leukemia. ( Bodey, GP; Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB, 1983) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 6.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties." | 6.65 | Mitoxantrone in relapsed and refractory acute leukemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984) |
| "Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis (RENEW) was a 5-year, phase IV study in which the safety of Mitoxantrone was monitored in a patient cohort from the United States (US)." | 5.17 | Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. ( Bock, D; Dangond, F; Jeffery, DR; Rivera, VM; Weinstock-Guttman, B, 2013) |
| " Flavopiridol given by 1-hour bolus at 50 mg/m(2) daily 3 times followed by cytosine arabinoside and mitoxantrone (FLAM) is active in adults with poor-risk acute leukemias." | 5.15 | Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. ( Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M, 2011) |
| "To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia." | 5.10 | Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. ( Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL, 2002) |
| "The present study was undertaken to assess the feasibility, toxicity and antileukemic activity of sequential chemotherapy including mitoxantrone, etoposide, carboplatin and intermediate-dose cytarabine in adult patients with refractory and relapsed acute myelogenous (AML) or lymphoid (ALL) leukemia." | 5.09 | Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia. ( Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J, 2000) |
| "A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent." | 5.08 | Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. ( Audhuy, B; Berthou, C; Cahn, JY; Caillot, D; Casassus, P; Colombat, P; Desablens, B; Guyotat, D; Harousseau, JL; Ifrah, N; Lamy, Y; Maloisel, F; Moreau, P; Pignon, B; Sadoun, A; Solary, E; Witz, B, 1996) |
| "Sixteen adult patients with relapsed (7 patients) or refractory (9 patients) acute leukemia received mitoxantrone (10 mg/m2 per day for 3 days) and etoposide (200 mg/m2 per day for 3 days) with escalating dose of cyclosporin A (CsA) from a loading dose of 2 mg to 6." | 5.07 | Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). ( Bastie, JN; Baumelou, E; Casassus, P; Coloma, F; Delmas-Marsalet, B; Delmer, A; Faussat Suberville, AM; Leroux, G; Marie, JP; Rio, B, 1993) |
| "Twenty-two patients with relapsed or refractory acute leukemia received 31 treatment courses of mitoxantrone (10 to 12 mg/m2/d) as a one-hour infusion for five days." | 5.06 | A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. ( Choi, KE; Daly, KM; Han, DS; Larson, RA; Sinkule, JA, 1987) |
| "BHAC-MMP therapy, a combination of behenoyl-ara-C, mitoxantrone, 6-mercaptopurine and prednisolone, was applied to 49 patients with acute leukemia for remission induction." | 5.06 | [A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kanamaru, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Shibata, H; Yasunaga, K; Yonezawa, T, 1986) |
| "A total of 47 patients with relapsed or primarily refractory leukemia were treated with mitoxantrone alone or in combination with vincristine sulfate and prednisone or cytarabine." | 5.05 | Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. ( Cuttner, J; Holland, JF; Paciucci, PA, 1984) |
| "Therapy-related acute leukaemia (TRAL) is a significant concern, when considering treatment with mitoxantrone for multiple sclerosis (MS)." | 4.91 | Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited? ( Boggild, M; Brown, S; Ellis, R, 2015) |
| "Despite the long-standing and extensive use of mitoxantrone (MTZ) for the treatment of aggressive forms of multiple sclerosis (MS), especially in Europe, its benefit-risk profile remains controversial." | 4.89 | Mitoxantrone-related acute leukemia in MS: an open or closed book? ( Chan, A; Lo-Coco, F, 2013) |
| "The accumulated Class III and IV evidence suggests an increased incidence of systolic dysfunction and therapy-related acute leukemia (TRAL) with mitoxantrone therapy." | 4.86 | Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. ( Gronseth, G; Marriott, JJ; Miyasaki, JM; O'Connor, PW, 2010) |
| "Mitoxantrone, an immunosuppressant agent with potent anti-inflammatory activity, has been used to treat patients with multiple sclerosis (MS) who have worsening relapsing-remitting (RRMS) or secondary progressive multiple sclerosis (SPMS) despite prior therapy with interferons or glatiramer acetate." | 4.83 | The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? ( Murray, TJ, 2006) |
| "Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events." | 4.82 | Mitoxantrone treatment of multiple sclerosis: safety considerations. ( Cohen, BA; Mikol, DD, 2004) |
| "To evaluate the incidence of therapy-related acute leukaemia (t-AL) after single-agent mitoxantrone (MITO) treatment, we reviewed medical records of patients in three studies of single-agent MITO therapy for multiple sclerosis (MS) and existing literature on MITO therapy in MS, leukaemia, and solid tumors." | 4.81 | A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. ( Butine, MD; De Goodkin, DE; Edan, G; Eisenmann, S; Ghalie, RG; Gonsette, RE; Hartung, HP; Le Page, E; Mauch, E, 2002) |
| "New clinical strategies and innovative approaches to the use of mitoxantrone include high-dose treatment, new combinations such as 5-fluorouracil with leucovorin (NFL), and neoadjuvant therapy for metastatic and primary breast cancer." | 4.79 | Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction. ( Powles, TJ, 1997) |
| "Mitoxantrone, a cytotoxic anthracenedione derivative, has given clinical evidence of beneficial activity in breast cancer, lymphoma and leukaemia." | 4.78 | Pharmacokinetics and metabolism of mitoxantrone. A review. ( Blanz, J; Ehninger, G; Proksch, B; Schuler, U; Zeller, KP, 1990) |
| "Two cases of therapy-related acute leukemia (TRAL) after the use of Mitoxantrone for the treatment of secondary progressive multiple sclerosis (MS) are reported." | 3.78 | Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone. ( Colovic, N; Dencic Fekete, M; Djordjevic, V; Drulovic, J; Kraguljac Kurtovic, N; Suvajdzic, N; Tomin, D; Vidovic, A, 2012) |
| "5 years suggests that the risk of either therapy-related acute leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis is low when patients are treated within standard protocol." | 3.78 | Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. ( Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012) |
| "Mitoxantrone is highly efficacious in the treatment of severe multiple sclerosis (MS)." | 3.76 | [Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia]. ( Ansorge, N; Chan, A; Dührsen, U; Gold, R; Meyer, C; Nückel, H; Ritter, PR; Salmen, S; Schmidt, WE; Siglienti, I; Stroet, A, 2010) |
| "In breast cancer, mitoxantrone's response rate as a single agent is 25-30%, while combination regimens produce response rates of 60% or more." | 3.76 | Mitoxantrone: a novel anthracycline derivative. ( Eble, M; Koeller, J, 1988) |
| "Mitoxantrone (Mx) is used as a second-line treatment in multiple sclerosis." | 3.73 | [Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone]. ( Baldauf, E; Berger, E; Deconinck, E; Nollet, S; Rumbach, L, 2006) |
| "The combination of adjuvant radiotherapy and chemotherapy with mitoxantrone induces a high risk of acute leukemia in patients with breast cancer." | 3.70 | Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. ( Bonithon-Kopp, C; Carli, PM; Chaplain, G; Milan, C; Sgro, C, 2000) |
| "Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF." | 3.70 | Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L, 1999) |
| "The objective of this study was to determine the response rate and toxicity of high-dose cytosine arabinoside (AC) and mitoxantrone (M) in relapsed or refractory childhood acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) and to correlate response with the expression of the multidrug resistance gene 1 (mdr1)." | 3.69 | Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. ( Cairo, MS; Feusner, J; Gold, SH; Knoppell, E; Krill, CE; Moulton, TA; Odom, LF; Waldron, P; Wells, RJ; White, ML, 1994) |
| "Fifteen adult patients with relapsed or refractory acute leukemia were treated with quinine formiate (30 mg/kg/d in continuous intravenous (IV) infusion from day 1 through day 5 or 6) associated with Ara-C (1 g/m2 in 3-hour IV infusion twice a day for 5 days) and five increasing doses of mitoxantrone (from 8 mg/m2/d for 4 days to 12 mg/m2/d for 5 days)." | 3.68 | Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. ( Caillot, D; Casasnovas, RO; Chauffert, B; Dumas, M; Guy, H; Maynadie, M; Solary, E, 1992) |
| "Fourteen patients with relapsed or refractory acute leukemia received combination chemotherapy of mitoxantrone 6 mg/m2/day intravenously for three to six days and cytosine arabinoside 60 mg/m2/day intravenously over 24 hours continuously for five to ten days." | 3.68 | [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia]. ( Fujiwara, Y; Murase, T; Ohkita, T; Tanaka, M; Uchida, T; Wakita, A, 1992) |
| "Forty-six patients with acute leukemia were treated with mitoxantrone as a single agent." | 3.67 | Mitoxantrone in the treatment of acute leukemia. ( Coccia-Portugal, MA; Falkson, G; Terblanche, AP; Vorobiof, DA, 1987) |
| "A phase II study of acute leukemia with mitoxantrone (MIT) was conducted by the Tokai Blood Cancer Study Group." | 3.67 | [Phase II study of mitoxantrone in patients with acute leukemia]. ( Hirano, M; Ikeda, Y; Kimura, K; Kobayashi, M; Ohara, K; Ohta, K; Shirakawa, S; Yamada, K; Yoshikawa, H; Yoshikawa, S, 1986) |
| "A total of seventeen patients with acute leukemia were treated with mitoxantrone for induction therapy." | 3.67 | [Phase II study of mitoxantrone for acute leukemia]. ( Hirayama, F; Kanakura, Y; Kubota, Y; Masaoka, T; Nakamura, H; Oguma, S; Shibata, H; Tani, Y; Tatsumi, Y; Ueda, T, 1984) |
| "A phase II study of mitoxantrone was conducted on acute leukemia." | 3.67 | [A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1986) |
| "The plasma kinetics of mitoxantrone (MX), a new cytostatic anthracenedione, were investigated with HPLC in five leukemic patients suffering from acute myeloid leukemia, at the dose of 24 mg m-2 infused over 30 min at constant rate." | 3.67 | Plasma kinetics of mitoxantrone in leukemic patients. ( Dumont, E; Harvengt, C; Hulhoven, R, 1984) |
| "Among new drugs being studied currently, AMSA and mitoxantrone have shown significant usefulness against acute non-lymphocytic leukemia in adults." | 3.67 | [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults]. ( Ogawa, M, 1986) |
| "Mitoxantrone was evaluated in a multi-institution trial to define the effective dose for treating acute leukemia, to evaluate its toxicity, and to assess the induction rates for the different types of acute leukemia." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia. ( Arlin, ZA; Armentrout, S; Cassileth, P; Coleman, M; Daghestani, A; Dukart, G; Gams, R; Schoch, I; Silver, R, 1985) |
| "A multidrug-resistant variant of the human HL-60 promyelocytic leukemia cell line (HL-60/MX2) has been isolated in vitro by subculturing these cells in progressively increasing concentrations of mitoxantrone." | 3.67 | Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. ( Dalton, WS; Harker, WG; Meltzer, PS; Slade, DL; Trent, JM, 1989) |
| "Mitoxantrone was administered as a single iv injection once every 3 weeks to 84 children with advanced acute leukemia and solid tumors in a phase I trial." | 3.67 | Phase I trial of mitoxantrone in children. ( Cohen, LF; Glaubiger, DL; Holcenberg, JS; Kamen, BA; Pratt, CB; Ungerleider, RS; Vietti, TJ, 1985) |
| "A phase II study of mitoxantrone (Novantrone; dihydroxyanthracenedione) was conducted in 35 patients (22 male: 13 female) with acute leukemia." | 3.67 | A phase II study of mitoxantrone in acute leukemia. ( Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1985) |
| "Thirty cases of acute leukemia in patients over 15 years of age (18 males and 12 females) were treated with combinations containing mitoxantrone between January 1986 and August 1987 at the Kuwait Cancer Control Center." | 3.67 | Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. ( Baker, H; Fayyaz, S; Khalifa, F; Salfiti, R; Samir Motawy, M, 1989) |
| "Seventeen patients with relapsed or refractory acute nonlymphocytic leukemia were treated with 14 mg/m2 of mitoxantrone given in a 30-minute infusion daily for three days." | 3.67 | Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. ( Ball, ED; Cornell, CJ; Cornwell, GG; McIntyre, OR; Mills, LE; O'Donnell, JF; Vredenburgh, JJ, 1988) |
| "We evaluated the effect of mitoxantrone (Novantrone; dihydroxyanthracenedione) in the treatment of refractory acute leukemia and acute leukemia in relapse." | 3.67 | Phase I-II trial of mitoxantrone in acute leukemia: an interim report. ( Arlin, ZA; Bertino, J; Cassileth, P; Dukart, G; Gams, R; Moore, J; Reisman, A; Schoch, I; Silver, RA, 1985) |
| "Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone." | 3.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Heidemann, E; Ho, AD; Meyer, P; Mjaaland, I; Seither, E, 1985) |
| "Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984." | 3.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986) |
| "Twenty-four patients with acute leukemia and blast crisis of chronic myelocytic leukemia in relapse or refractory to standard chemotherapy were eligible for treatment with mitoxantrone." | 3.67 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. ( Ehninger, G; Ho, AD; Meyer, P; Mjaaland, I; Ostendorf, P; Seither, E, 1985) |
| "Mitoxantrone, a new anthracenedione, was administered to twenty-five evaluable patients with relapsed or refractory acute leukemia between January 1982 and September 1984." | 3.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Hattori, M; Kaneko, Y; Kumai, R; Maseki, N; Sakurai, M; Sampi, K, 1985) |
| "Eleven patients with acute leukemia were treated with MB-triple V therapy consisting of mitoxantrone, behenoyl-arabinoside, etoposide, vincristine and vindesine." | 3.67 | [Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy]. ( Furukawa, Y; Im, T; Inoue, T; Kishida, T; Park, K; Sasaki, A; Tatsumi, N; Yamane, T, 1989) |
| "Nine children with acute non-lymphocytic leukemia (ANLL), ages 16 months to 16 years (median 7 years), and 15 children with acute lymphocytic leukemia (ALL), ages 10 months to 18 years (median 5 years), were treated with 5-day courses of mitoxantrone (Novantrone; dihydroxyanthracenedione) as induction therapy." | 3.67 | Mitoxantrone in refractory acute leukemia in children: a phase I study. ( Dukart, G; Mulne, AF; Schoch, I; Starling, KA; Vats, TS, 1985) |
| "Twenty-six patients with acute leukemia in relapse were treated with mitoxantrone (dihydroxyanthracenedione dihydrochloride)." | 3.66 | Mitoxantrone in patients with acute leukemia in relapse. ( Cuttner, J; Holland, JF; Ohnuma, T; Paciucci, PA; Silver, RT, 1983) |
| "Mitoxantrone was administered to 41 adults with refractory acute leukemia." | 3.66 | Phase II trial of mitoxantrone in refractory acute leukemia. ( Bodey, GP; Estey, EH; Freireich, EJ; Keating, MJ; McCredie, KB, 1983) |
| "Mitoxantrone was subsequently given in a five-day schedule at a dose of 10mg/m2 daily to twenty-one patients with relapsed or refractory acute leukaemia or chronic myeloid leukaemia in blast crisis (CML-BC)." | 2.66 | Sequential studies on the role of mitoxantrone in the treatment of acute leukemia. ( Prentice, HG; Robbins, G; Wimperis, JZ, 1985) |
| "Mitoxantrone is an active and relatively non-toxic agent which merits further assessment prior to its incorporation in first-line therapy of acute leukaemia." | 2.65 | Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1983) |
| "Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties." | 2.65 | Mitoxantrone in relapsed and refractory acute leukemia. ( Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984) |
| " The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents." | 1.35 | The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. ( Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009) |
| "The most frequent cancers were breast (34." | 1.35 | Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. ( Berthier, F; Clavelou, P; Danzon, A; de Seze, J; Debouverie, M; Defer, G; Gout, O; Lebrun, C; Rumbach, L; Vermersch, P; Wiertlevski, S, 2008) |
| "Verapamil did not increase DNR toxicity in four of these eight cases, but was more efficient in one other MDR1(+) case." | 1.30 | Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells. ( Faussat, AM; Marie, JP; Simonin, G; Zhou, DC; Zittoun, R, 1997) |
| "Mitoxantrone was extracted directly from plasma samples with a plastic mini-column packed with non-bonded silica gel and eluted with the above elution solvent." | 1.28 | High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation. ( Leclerc, JM; Lin, KT; Rivard, GE, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 59 (45.74) | 18.7374 |
| 1990's | 28 (21.71) | 18.2507 |
| 2000's | 24 (18.60) | 29.6817 |
| 2010's | 15 (11.63) | 24.3611 |
| 2020's | 3 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mei, SX | 1 |
| Jiang, B | 1 |
| Niu, XM | 1 |
| Li, ML | 1 |
| Yang, H | 1 |
| Na, Z | 1 |
| Lin, ZW | 1 |
| Li, CM | 1 |
| Sun, HD | 1 |
| Das, SG | 1 |
| Doshi, JM | 1 |
| Tian, D | 1 |
| Addo, SN | 1 |
| Srinivasan, B | 1 |
| Hermanson, DL | 1 |
| Xing, C | 1 |
| Nguyen, HT | 1 |
| Song, GY | 1 |
| Kim, JA | 1 |
| Hyun, JH | 1 |
| Kang, HK | 1 |
| Kim, YH | 1 |
| Li, B | 1 |
| Hu, M | 1 |
| Chen, C | 1 |
| Yin, H | 1 |
| Deng, Y | 1 |
| Li, H | 1 |
| Zhang, J | 1 |
| He, L | 1 |
| Kim, H | 1 |
| Jung, I | 1 |
| Lee, CH | 1 |
| An, J | 1 |
| Ko, M | 1 |
| Jing, W | 1 |
| Zhou, M | 1 |
| Chen, R | 1 |
| Ye, X | 1 |
| Li, W | 1 |
| Su, X | 1 |
| Luo, J | 1 |
| Wang, Z | 1 |
| Peng, S | 1 |
| Chan, A | 2 |
| Lo-Coco, F | 1 |
| Shi, Y | 1 |
| Su, Z | 1 |
| Li, S | 1 |
| Chen, Y | 1 |
| Chen, X | 1 |
| Xiao, Y | 1 |
| Sun, M | 1 |
| Ping, Q | 1 |
| Zong, L | 1 |
| Rivera, VM | 1 |
| Jeffery, DR | 1 |
| Weinstock-Guttman, B | 1 |
| Bock, D | 1 |
| Dangond, F | 1 |
| Kostrzewa-Nowak, D | 1 |
| Tarasiuk, J | 1 |
| Ellis, R | 1 |
| Brown, S | 1 |
| Boggild, M | 1 |
| Deeren, D | 1 |
| Tanaka, M | 2 |
| Kano, Y | 2 |
| Akutsu, M | 2 |
| Tsunoda, S | 2 |
| Izumi, T | 2 |
| Yazawa, Y | 1 |
| Miyawaki, S | 1 |
| Mano, H | 2 |
| Furukawa, Y | 3 |
| Marriott, JJ | 1 |
| Miyasaki, JM | 1 |
| Gronseth, G | 1 |
| O'Connor, PW | 1 |
| Gopinath, SC | 1 |
| Wadhwa, R | 1 |
| Kumar, PK | 1 |
| Meyer, C | 1 |
| Ansorge, N | 1 |
| Siglienti, I | 1 |
| Salmen, S | 1 |
| Stroet, A | 1 |
| Nückel, H | 1 |
| Dührsen, U | 1 |
| Ritter, PR | 1 |
| Schmidt, WE | 1 |
| Gold, R | 1 |
| Karp, JE | 1 |
| Smith, BD | 1 |
| Resar, LS | 1 |
| Greer, JM | 1 |
| Blackford, A | 1 |
| Zhao, M | 1 |
| Moton-Nelson, D | 1 |
| Alino, K | 1 |
| Levis, MJ | 1 |
| Gore, SD | 1 |
| Joseph, B | 1 |
| Carraway, H | 1 |
| McDevitt, MA | 1 |
| Bagain, L | 1 |
| Mackey, K | 1 |
| Briel, J | 1 |
| Doyle, LA | 1 |
| Wright, JJ | 1 |
| Rudek, MA | 1 |
| Le Page, E | 2 |
| Leray, E | 1 |
| Edan, G | 2 |
| Gupta, A | 1 |
| Le, A | 1 |
| Belinka, BA | 1 |
| Kachlany, SC | 1 |
| Mulroy, E | 1 |
| Joyce, E | 1 |
| Scott, J | 1 |
| Melling, J | 1 |
| Goggin, C | 1 |
| Mahon, N | 1 |
| O'Rourke, K | 1 |
| Lynch, T | 1 |
| Colovic, N | 1 |
| Suvajdzic, N | 1 |
| Kraguljac Kurtovic, N | 1 |
| Djordjevic, V | 1 |
| Dencic Fekete, M | 1 |
| Drulovic, J | 1 |
| Vidovic, A | 1 |
| Tomin, D | 1 |
| Cowell, IG | 1 |
| Austin, CA | 1 |
| Mainwaring, MG | 1 |
| Rimsza, LM | 1 |
| Chen, SF | 1 |
| Gomez, SP | 1 |
| Weeks, FW | 1 |
| Reddy, V | 1 |
| Lynch, J | 1 |
| May, WS | 1 |
| Kahn, S | 1 |
| Moreb, J | 1 |
| Leather, H | 1 |
| Braylan, R | 1 |
| Rowe, TC | 1 |
| Fieniewicz, KJ | 1 |
| Wingard, JR | 1 |
| Ghalie, RG | 1 |
| Mauch, E | 1 |
| Hartung, HP | 1 |
| Gonsette, RE | 1 |
| Eisenmann, S | 1 |
| Butine, MD | 1 |
| De Goodkin, DE | 1 |
| Cohen, BA | 1 |
| Mikol, DD | 1 |
| Seiter, K | 2 |
| Güven, GS | 1 |
| Ozçakar, L | 1 |
| Koçak, T | 1 |
| Aksu, S | 1 |
| Kogoshi, H | 1 |
| Tohda, S | 1 |
| Fu, L | 1 |
| Koyama, T | 1 |
| Nara, N | 1 |
| Kansu, E | 1 |
| Koc, Y | 1 |
| Kars, A | 1 |
| Alakavuklar, M | 1 |
| Tekuzman, G | 1 |
| Firat, D | 1 |
| Murray, TJ | 1 |
| Nollet, S | 1 |
| Berger, E | 1 |
| Deconinck, E | 1 |
| Baldauf, E | 1 |
| Rumbach, L | 2 |
| Vu, HA | 1 |
| Odgerel, T | 1 |
| Matsuo, Y | 1 |
| Kirito, K | 1 |
| Sato, Y | 1 |
| Huang, XJ | 1 |
| Liu, DH | 1 |
| Liu, KY | 1 |
| Xu, LP | 1 |
| Chen, H | 1 |
| Han, W | 1 |
| Böttger, S | 1 |
| Jerszyk, E | 1 |
| Low, B | 1 |
| Walker, C | 1 |
| Lebrun, C | 1 |
| Debouverie, M | 1 |
| Vermersch, P | 1 |
| Clavelou, P | 1 |
| de Seze, J | 1 |
| Wiertlevski, S | 1 |
| Defer, G | 1 |
| Gout, O | 1 |
| Berthier, F | 1 |
| Danzon, A | 1 |
| Gahrton, G | 1 |
| Smith, IE | 1 |
| Cheng, CC | 1 |
| Zee-Cheng, RK | 1 |
| Prentice, HG | 5 |
| Robbins, G | 3 |
| Ma, DD | 3 |
| Ho, AD | 5 |
| Paciucci, PA | 2 |
| Cuttner, J | 2 |
| Holland, JF | 2 |
| Moore, JO | 2 |
| Olsen, GA | 1 |
| Nathanson, L | 1 |
| Hulhoven, R | 1 |
| Dumont, E | 1 |
| Harvengt, C | 1 |
| Masaoka, T | 6 |
| Ueoka, H | 1 |
| Ueno, K | 1 |
| Yamane, T | 2 |
| Toyoda, K | 1 |
| Endo, H | 1 |
| Nishihara, R | 1 |
| Takahashi, I | 1 |
| Ohnoshi, T | 2 |
| Kitajima, K | 1 |
| Kimura, I | 2 |
| Oguma, S | 3 |
| Tatsumi, Y | 1 |
| Hirayama, F | 1 |
| Tani, Y | 1 |
| Kubota, Y | 1 |
| Kanakura, Y | 1 |
| Ueda, T | 1 |
| Nakamura, H | 1 |
| Shibata, H | 4 |
| Dalton, WS | 2 |
| Alberts, DS | 1 |
| Estey, EH | 2 |
| Keating, MJ | 2 |
| McCredie, KB | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Ohnuma, T | 1 |
| Silver, RT | 1 |
| Macdonald, JS | 1 |
| Marsoni, S | 1 |
| Bruno, S | 1 |
| Poster, D | 1 |
| Meckenstock, G | 1 |
| Heyll, A | 1 |
| Schneider, EM | 1 |
| Hildebrandt, B | 1 |
| Runde, V | 1 |
| Aul, C | 1 |
| Bartram, CR | 1 |
| Ludwig, WD | 1 |
| Schneider, W | 1 |
| Wells, RJ | 1 |
| Odom, LF | 1 |
| Gold, SH | 1 |
| Feusner, J | 1 |
| Krill, CE | 1 |
| Waldron, P | 1 |
| Moulton, TA | 1 |
| Knoppell, E | 1 |
| White, ML | 1 |
| Cairo, MS | 1 |
| Solary, E | 4 |
| Witz, F | 1 |
| Moreau, P | 2 |
| Quiquandon, I | 1 |
| Genne, P | 1 |
| Flesch, M | 1 |
| Saddoun, A | 1 |
| Maloisel, F | 3 |
| Pignon, B | 2 |
| Abgrall, JF | 1 |
| Marie, JP | 2 |
| Bastie, JN | 1 |
| Coloma, F | 1 |
| Faussat Suberville, AM | 1 |
| Delmer, A | 1 |
| Rio, B | 1 |
| Delmas-Marsalet, B | 1 |
| Leroux, G | 1 |
| Casassus, P | 3 |
| Baumelou, E | 1 |
| Lyytikäinen, O | 1 |
| Elonen, E | 1 |
| Lautenschlager, I | 1 |
| Jokipii, A | 1 |
| Tiittanen, L | 1 |
| Ruutu, P | 1 |
| Gandhi, V | 1 |
| Plunkett, W | 2 |
| Witz, B | 1 |
| Caillot, D | 2 |
| Desablens, B | 1 |
| Cahn, JY | 1 |
| Sadoun, A | 1 |
| Berthou, C | 1 |
| Guyotat, D | 1 |
| Ifrah, N | 1 |
| Lamy, Y | 1 |
| Audhuy, B | 1 |
| Colombat, P | 1 |
| Harousseau, JL | 1 |
| Doi, T | 1 |
| Sakamaki, S | 1 |
| Koike, K | 1 |
| Matsunaga, T | 1 |
| Kobayashi, D | 1 |
| Muramatsu, H | 1 |
| Sato, T | 1 |
| Watanabe, N | 1 |
| Kougo, Y | 1 |
| Niitsu, Y | 1 |
| Vial, JP | 1 |
| Belloc, F | 1 |
| Dumain, P | 1 |
| Besnard, S | 1 |
| Lacombe, F | 1 |
| Boisseau, MR | 1 |
| Reiffers, J | 2 |
| Bernard, P | 1 |
| Brodsky, AL | 1 |
| Melero, MJ | 1 |
| Minissale, CJ | 1 |
| Sánchez Avalos, JC | 1 |
| Asschert, J | 1 |
| de Vries, E | 1 |
| van der Kolk, D | 1 |
| Müller, M | 1 |
| Vellenga, E | 1 |
| Zhou, DC | 1 |
| Simonin, G | 1 |
| Faussat, AM | 1 |
| Zittoun, R | 1 |
| Powles, TJ | 1 |
| Killick, S | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Wattel, E | 1 |
| Leleu, X | 1 |
| Dreyfus, F | 1 |
| Brion, A | 1 |
| Jouet, JP | 1 |
| Hoang-Ngoc, L | 1 |
| Guerci, A | 1 |
| Rochant, H | 1 |
| Gratecos, N | 1 |
| Janvier, M | 1 |
| Brice, P | 1 |
| Lepelley, P | 1 |
| Fenaux, P | 1 |
| Alessandrino, EP | 1 |
| Bernasconi, P | 1 |
| Caldera, D | 1 |
| Colombo, A | 1 |
| Malcovati, L | 1 |
| Martinelli, G | 1 |
| Bonfichi, M | 1 |
| Pagnucco, G | 1 |
| Salvaneschi, L | 1 |
| Bernasconi, C | 2 |
| Macnamara, B | 1 |
| Palucka, KA | 1 |
| Porwit-MacDonald, A | 1 |
| Salvucci, M | 1 |
| Zanchini, R | 1 |
| Molinari, A | 1 |
| Zuffa, E | 1 |
| Poletti, V | 1 |
| Poletti, G | 1 |
| Zaccaria, A | 1 |
| Chaplain, G | 1 |
| Milan, C | 1 |
| Sgro, C | 1 |
| Carli, PM | 1 |
| Bonithon-Kopp, C | 1 |
| Bajwa, RP | 1 |
| Skinner, R | 1 |
| Windebank, KP | 1 |
| Wariyar, UK | 1 |
| Reid, MM | 1 |
| Nair, JS | 1 |
| Kancherla, R | 1 |
| Traganos, F | 1 |
| Tse-Dinh, YC | 1 |
| Ferrá, C | 1 |
| Berlanga, JJ | 1 |
| Gallardo, D | 1 |
| Ancín, I | 1 |
| Marín, D | 1 |
| González, JR | 1 |
| Peris, J | 1 |
| Muñoz, J | 1 |
| Sarrá, J | 1 |
| Grañena, A | 1 |
| Kern, W | 1 |
| Schleyer, E | 1 |
| Braess, J | 1 |
| Wittmer, E | 1 |
| Ohnesorge, J | 1 |
| Unterhalt, M | 1 |
| Wörmann, B | 1 |
| Büchner, T | 2 |
| Hiddemann, W | 2 |
| Budman, DR | 1 |
| Calabro, A | 1 |
| Kreis, W | 1 |
| Rizzieri, DA | 1 |
| Bass, AJ | 1 |
| Rosner, GL | 1 |
| Gockerman, JP | 1 |
| DeCastro, CM | 1 |
| Petros, WP | 1 |
| Adams, DJ | 1 |
| Laughlin, MJ | 1 |
| Davis, P | 1 |
| Foster, T | 1 |
| Jacobson, R | 1 |
| Hurwitz, H | 1 |
| Takahashi, A | 1 |
| Yamamoto, K | 1 |
| Okuma, M | 1 |
| Sasada, M | 1 |
| Chauffert, B | 1 |
| Casasnovas, RO | 1 |
| Dumas, M | 1 |
| Maynadie, M | 1 |
| Guy, H | 1 |
| Wakita, A | 1 |
| Murase, T | 1 |
| Uchida, T | 1 |
| Fujiwara, Y | 1 |
| Ohkita, T | 1 |
| Birchall, LA | 1 |
| Bailey, NP | 1 |
| Blackledge, GR | 1 |
| Heinemann, V | 1 |
| Estey, E | 1 |
| Keating, M | 1 |
| Ehninger, G | 3 |
| Schuler, U | 1 |
| Proksch, B | 1 |
| Zeller, KP | 1 |
| Blanz, J | 1 |
| Kumar, L | 1 |
| Kochipillai, V | 1 |
| Coccia-Portugal, MA | 2 |
| Falkson, G | 2 |
| Uys, A | 1 |
| Kusnierz-Glaz, C | 1 |
| Reiser, M | 1 |
| Hagemeister, B | 1 |
| van de Loo, J | 1 |
| Marit, G | 1 |
| Cony, P | 1 |
| Duclos, F | 1 |
| Puntous, M | 1 |
| Broustet, A | 1 |
| Cunningham, M | 1 |
| Ohtsu, T | 2 |
| Ishida, Y | 2 |
| Tobinai, K | 2 |
| Minato, K | 2 |
| Hamada, H | 2 |
| Ohkochi, E | 1 |
| Tsuruo, T | 2 |
| Shimoyama, M | 2 |
| Lin, KT | 1 |
| Rivard, GE | 1 |
| Leclerc, JM | 1 |
| Harker, WG | 1 |
| Slade, DL | 1 |
| Meltzer, PS | 1 |
| Trent, JM | 1 |
| Sugimoto, Y | 1 |
| Inoue, T | 1 |
| Sasaki, A | 1 |
| Kishida, T | 1 |
| Park, K | 1 |
| Im, T | 1 |
| Tatsumi, N | 1 |
| Coiffier, B | 1 |
| Samir Motawy, M | 1 |
| Salfiti, R | 1 |
| Khalifa, F | 1 |
| Fayyaz, S | 1 |
| Baker, H | 1 |
| Young, CW | 1 |
| Raymond, V | 1 |
| Koeller, J | 1 |
| Eble, M | 1 |
| Cotter, FE | 1 |
| Takeyama, H | 1 |
| Fukutani, H | 1 |
| Takeo, T | 1 |
| Yamada, H | 1 |
| Watanabe, E | 1 |
| Tsukagoshi, S | 1 |
| Petti, MC | 1 |
| Avvisati, G | 1 |
| Tafuri, A | 1 |
| Meloni, G | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Vredenburgh, JJ | 1 |
| McIntyre, OR | 1 |
| Cornwell, GG | 1 |
| Ball, ED | 1 |
| Cornell, CJ | 1 |
| Mills, LE | 1 |
| O'Donnell, JF | 1 |
| Okuma, K | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Sampi, K | 2 |
| Ogawa, M | 2 |
| Yamada, K | 3 |
| Wakui, A | 1 |
| Meguro, S | 1 |
| Nagai, K | 4 |
| Kitani, T | 4 |
| Seither, E | 3 |
| Vorobiof, DA | 1 |
| Terblanche, AP | 1 |
| Shenkenberg, TD | 1 |
| Von Hoff, DD | 1 |
| Kanamaru, A | 1 |
| Horiuchi, A | 3 |
| Yonezawa, T | 3 |
| Kawagoe, H | 3 |
| Yasunaga, K | 3 |
| Kimura, K | 2 |
| Yoshikawa, H | 2 |
| Yoshikawa, S | 2 |
| Hirano, M | 2 |
| Ikeda, Y | 2 |
| Ohta, K | 2 |
| Ohno, R | 1 |
| Ohara, K | 2 |
| Kobayashi, M | 2 |
| Larson, RA | 2 |
| Daly, KM | 2 |
| Choi, KE | 2 |
| Han, DS | 2 |
| Sinkule, JA | 2 |
| Sanz, MA | 1 |
| Martínez, J | 1 |
| Borrego, D | 1 |
| Martín-Aragonés, G | 1 |
| Lorenzo, I | 1 |
| Sanz, G | 1 |
| Sayas, MJ | 1 |
| Jarque, I | 1 |
| Pastor, E | 1 |
| Rafecas, J | 1 |
| McGrath, SC | 1 |
| Spitzer, T | 1 |
| Gerson, S | 1 |
| Lazarus, H | 1 |
| Shirakawa, S | 1 |
| Arlin, ZA | 2 |
| Silver, R | 1 |
| Cassileth, P | 2 |
| Armentrout, S | 1 |
| Gams, R | 2 |
| Daghestani, A | 1 |
| Coleman, M | 1 |
| Schoch, I | 3 |
| Dukart, G | 3 |
| Ungerleider, RS | 1 |
| Pratt, CB | 1 |
| Vietti, TJ | 1 |
| Holcenberg, JS | 1 |
| Kamen, BA | 1 |
| Glaubiger, DL | 1 |
| Cohen, LF | 1 |
| Meyer, P | 2 |
| Mjaaland, I | 2 |
| Heidemann, E | 1 |
| Reisman, A | 1 |
| Moore, J | 1 |
| Silver, RA | 1 |
| Bertino, J | 1 |
| Wimperis, JZ | 1 |
| Ostendorf, P | 1 |
| Klein, HO | 1 |
| Kaneko, Y | 1 |
| Maseki, N | 1 |
| Kumai, R | 1 |
| Sakurai, M | 1 |
| Hattori, M | 1 |
| Starling, KA | 1 |
| Mulne, AF | 1 |
| Vats, TS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leu[NCT00470197] | Phase 1 | 35 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522] | Phase 2 | 23 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 reviews available for mitoxantrone and Leukemia
| Article | Year |
|---|---|
Mitoxantrone-related acute leukemia in MS: an open or closed book?
Topics: Antineoplastic Agents, Alkylating; Humans; Leukemia; Mitoxantrone; Monitoring, Physiologic; Multiple | 2013 |
Therapy-related acute leukaemia with mitoxantrone: four years on, what is the risk and can it be limited?
Topics: Antineoplastic Agents; Humans; Leukemia; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relap | 2015 |
Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Topics: Adult; Cardiotoxins; Controlled Clinical Trials as Topic; Databases, Factual; Female; Humans; Leukem | 2010 |
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis.
Topics: Acute Disease; Adolescent; Adult; Aged; Clinical Trials, Phase III as Topic; Female; France; Germany | 2002 |
Mitoxantrone treatment of multiple sclerosis: safety considerations.
Topics: Animals; Cardiomyopathies; Drug Monitoring; Heart Failure; Humans; Immunosuppressive Agents; Leukemi | 2004 |
Toxicity of the topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirub | 2005 |
The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?
Topics: Disease Progression; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia; Mitoxantrone | 2006 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinone | 1983 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
The design, synthesis and development of a new class of potent antineoplastic anthraquinones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Clini | 1983 |
Intracellular pharmacodynamics in leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cytarabine; H | 1996 |
Evolving clinical strategies: innovative approaches to the use of mitoxantrone--introduction.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Leukemia; Lymphoma; Mitoxantrone | 1997 |
An overview of mitozantrone.
Topics: Acute Disease; Breast Neoplasms; Female; Humans; Leukemia; Mitoxantrone; Neoplasms | 1991 |
Pharmacologically directed design of leukemia therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Arabinonucleo | 1990 |
Pharmacokinetics and metabolism of mitoxantrone. A review.
Topics: Animals; Breast Neoplasms; Chromatography, High Pressure Liquid; Humans; Infusions, Intravenous; Leu | 1990 |
Nonhematologic toxicities of selected chemotherapeutic agents used in the treatment of adult leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; | 1990 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Dise | 1989 |
Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Topics: Aclarubicin; Anthraquinones; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Cell Survival | 1986 |
Mitoxantrone: a novel anthracycline derivative.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi | 1988 |
Therapeutic milestones. Novantrone (mitozantrone).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Leukemia; Lymphoma | 1988 |
Mitoxantrone: a new anticancer drug with significant clinical activity.
Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T | 1986 |
26 trials available for mitoxantrone and Leukemia
| Article | Year |
|---|---|
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Topics: Adult; Aged; Female; Heart Failure; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Scle | 2013 |
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2011 |
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragment | 2002 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; | 2007 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
The design, synthesis and development of a new class of potent antineoplastic anthraquinones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Clini | 1983 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Cells, Cultured; Clinical Trials | 1983 |
Mitoxantrone in relapsed and refractory acute leukemia.
Topics: Acute Disease; Aged; Anthraquinones; Antineoplastic Agents; Cell Line; Clinical Trials as Topic; Fol | 1984 |
Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combin | 1984 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Clinical Trials as Topic; Drug Ad | 1984 |
Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1993 |
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study.
Topics: Acute Disease; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells | 1996 |
[Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anti | 1996 |
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1999 |
Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free | 2001 |
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2002 |
[Evaluation of mitoxantrone in 1989].
Topics: Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Leukemia; Lymphoma; Mal | 1989 |
Mitoxantrone: a novel anthracycline derivative.
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Humans; Leukemia; Lymphoma; Mi | 1988 |
The role of mitozantrone in the treatment of acute leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Clinical | 1987 |
[Introduction of a new anticancer drug, novantrone].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; | 1987 |
Mitoxantrone: a new anticancer drug with significant clinical activity.
Topics: Adult; Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Child; Clinical Trials as T | 1986 |
[A phase III study of BHAC-MMP (behenoyl-ara-C, mitoxantrone, 6-mercaptopurine prednisolone) in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protoco | 1986 |
[Mitoxantrone as combination chemotherapy in patients with acute leukemia. Tokai Blood Cancer Study Group].
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Clini | 1986 |
A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Female; | 1987 |
Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Agranulocytosis; Anthraquinones; Antineoplastic Agents; Bone | 1985 |
86 other studies available for mitoxantrone and Leukemia
| Article | Year |
|---|---|
Abietane diterpenoids from Coleus xanthanthus.
Topics: Antineoplastic Agents, Phytogenic; Diterpenes; Drug Screening Assays, Antitumor; Drugs, Chinese Herb | 2002 |
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Topics: Apoptosis; Benzopyrans; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia; | 2009 |
Dammarane-type saponins from the flower buds of Panax ginseng and their effects on human leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Dammaranes; Flowers; HL-60 Cells; Humans; Leukemia; Magnetic Reso | 2010 |
Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Screening As | 2022 |
Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins.
Topics: 5-Methylcytosine; Animals; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; | 2023 |
In vitro and ex vivo anti‑tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2‑overexpressing leukemia cells.
Topics: Adenosine Triphosphatases; Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily | 2021 |
Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Drug Delivery Systems; Durapatite; Fo | 2013 |
Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Multiple; HL-60 C | 2013 |
Treatment of invasive aspergillosis with nonmyeloablative allogeneic stem cell transplantation: the hunter becomes the hunted.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Cytarabine; Female; Hematopoie | 2008 |
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, | 2009 |
Expression of noncoding vault RNA in human malignant cells and its importance in mitoxantrone resistance.
Topics: Antineoplastic Agents; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; G | 2010 |
[Mitoxantrone-related acute leukemia by multiple sclerosis. Case report and practical approach by unclear cytopenia].
Topics: Adult; Analgesics; Humans; Leukemia; Male; Mitoxantrone; Multiple Sclerosis; Thrombocytopenia | 2010 |
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Topics: Adult; Amenorrhea; Female; France; Heart Failure; Humans; Immunologic Factors; Leukemia; Male; Middl | 2011 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busul | 2011 |
Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis.
Topics: Adult; Aged; Cardiomyopathies; Female; Follow-Up Studies; Humans; Leukemia; Male; Middle Aged; Mitox | 2012 |
Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
Topics: Acute Disease; Adult; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis, | 2012 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epir | 2012 |
Knee arthritis as a rare inaugural manifestation of adult leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cytarabine; Diagnosis, Differentia | 2005 |
Effect of notch ligands on in vitro sensitivity to chemo-therapeutic drugs in leukemia and lymphoma cells.
Topics: Antineoplastic Agents; Calcium-Binding Proteins; Caspase 3; Caspases; Cell Line, Tumor; Cell Prolife | 2005 |
Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clinical Trials as T | 1989 |
[Acute leukaemia in two multiple sclerosis patients treated with mitoxantrone].
Topics: Acute Disease; Adult; Analgesics; Blood Cell Count; Female; Humans; Leukemia; Middle Aged; Mitoxantr | 2006 |
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubici | 2007 |
Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.
Topics: Amino Acid Sequence; Animals; Apoptosis; DNA Damage; Etoposide; Fatty Acids, Unsaturated; Hemocytes; | 2008 |
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis.
Topics: Adult; Azathioprine; Breast Neoplasms; Central Nervous System Neoplasms; Cyclophosphamide; Digestive | 2008 |
Mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Drug Evaluation; Hear | 1984 |
Plasma kinetics of mitoxantrone in leukemic patients.
Topics: Anthraquinones; Antineoplastic Agents; Humans; Kinetics; Leukemia; Mitoxantrone | 1984 |
[Treatment of acute leukemia in relapse].
Topics: Acute Disease; Adult; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; H | 1983 |
[Phase II study of mitoxantrone for hematologic malignancies].
Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Hu | 1983 |
[Phase II study of mitoxantrone for acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Drug Administration Schedule; Drug Evaluation; Fem | 1984 |
Mitoxantrone: a promising new chemotherapeutic agent.
Topics: Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Humans; Leukemia; Mitoxant | 1984 |
Phase II trial of mitoxantrone in refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Administration S | 1983 |
Mitoxantrone in patients with acute leukemia in relapse.
Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Child; Drug Administration | 1983 |
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
Topics: Adenosine Deaminase Inhibitors; Aminoacridines; Amsacrine; Anthracenes; Antineoplastic Agents; Cofor | 1982 |
Acute leukemia coexpressing myeloid, B- and T-lineage associated markers: multiparameter analysis of criteria defining lineage commitment and maturational stage in a case of undifferentiated leukemia.
Topics: Acute Disease; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio | 1995 |
Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, | 1994 |
[Mitoxantrone-aracytine with or without quinine in the treatment of refractory or relapsed acute leukemia].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; | 1994 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmus | 1996 |
[CD7, HLA-DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma].
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD7; Antigens, Di | 1996 |
Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 1997 |
The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cyclosporins; Daunorubicin; | 1997 |
Effect of the multidrug inhibitor GG918 on drug sensitivity of human leukemic cells.
Topics: Acridines; Acute Disease; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane Per | 1997 |
Case 17: Essential thrombocythaemia with inversion 3 terminating in acute leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Hu | 1998 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined | 1999 |
Balance between proliferation and apoptosis in leukemic cell lines resistant to cytostatics.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, | 1999 |
Lung toxicity following fludarabine, cytosine arabinoside and mitoxantrone (flan) treatment for acute leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Hemorrhage; Humans; I | 2000 |
Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Coh | 2000 |
Chemotherapy and marrow transplantation for congenital leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplanta | 2001 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2000 |
In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?
Topics: Acute Disease; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cytarabin | 2001 |
Bone marrow stromal cells attenuate mitoxantrone cytotoxicity against HL-60 leukemic cells.
Topics: Cell Adhesion; Cell Survival; Fibroblasts; Hematopoietic Stem Cells; Humans; Leukemia; Mitoxantrone; | 1992 |
Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding | 1992 |
[Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cy | 1992 |
Mitoxantrone induced hyperpigmentation.
Topics: Acute Disease; Adult; Facial Dermatoses; Hand Dermatoses; Humans; Leukemia; Male; Mitoxantrone; Nail | 1990 |
Mitoxantrone in the treatment of acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Child, Preschool; Drug Evaluation; Female; Humans; Le | 1990 |
Magnetic resonance imaging follow-up in patients with acute leukemia during induction chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1990 |
A novel multidrug resistance in cultured leukemia and lymphoma cells detected by a monoclonal antibody to 85-kDa protein, MRK20.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Drug Resistance; Humans; Immunoglobulin Fab Fra | 1989 |
High-performance liquid chromatographic determination of mitoxantrone in plasma utilizing non-bonded silica gel for solid-phase isolation to reduce adsorptive losses on glass during sample preparation.
Topics: Chemical Phenomena; Chemistry; Chromatography, High Pressure Liquid; Humans; Leukemia; Mitoxantrone; | 1989 |
Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance; Gen | 1989 |
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Dauno | 1989 |
[Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluat | 1989 |
Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 1989 |
[Intermediate-dose cytosine arabinoside in combination with mitoxantrone in the treatment of refractory leukemia].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; M | 1988 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 1987 |
Mitoxantrone.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cytarabine; Daunoru | 1988 |
Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Drug Evaluation; Drug Resistance; Hema | 1988 |
[Cardiotoxicity of mitoxantrone].
Topics: Adolescent; Adult; Aged; Blast Crisis; Child; Doxorubicin; Electrocardiography; Female; Heart; Heart | 1986 |
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Blast Crisis; Child; Daunorubicin; Drug Evaluat | 1986 |
Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells.
Topics: Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Humans; Leukemia; Leukemia, Myeloid, Acute; Lym | 1987 |
Mitoxantrone in the treatment of acute leukemia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; Infant; Kidney Function Tests; Leu | 1987 |
High-dose cytosine arabinoside and mitoxantrone in high-risk acute nonlymphoblastic leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Rela | 1987 |
High-performance liquid chromatographic assay for mitoxantrone in plasma using electrochemical detection.
Topics: Chromatography, High Pressure Liquid; Electrochemistry; Humans; Leukemia; Mitoxantrone; Temperature | 1987 |
Prolonged disease-free survival in refractory acute nonlymphocytic leukemia using mitoxantrone.
Topics: Follow-Up Studies; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Remission Induction | 1987 |
[Phase II study of mitoxantrone in patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Drug Administr | 1986 |
[A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders].
Topics: Acute Disease; Adolescent; Adult; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Humans; In | 1986 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; | 1986 |
Mitozantrone.
Topics: Breast Neoplasms; Humans; Leukemia; Liver Neoplasms; Lymphoma; Mitoxantrone; Neoplasms | 1986 |
Phase I-II trial of mitoxantrone in acute leukemia.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Drug Evaluation; Female; Heart; Humans; Leukemia; Leukem | 1985 |
Phase I trial of mitoxantrone in children.
Topics: Acute Disease; Adolescent; Agranulocytosis; Anthraquinones; Child; Child, Preschool; Dose-Response R | 1985 |
A phase II study of mitoxantrone in acute leukemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Alanine Transaminase; Anthraquinones; Antineoplastic | 1985 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow | 1985 |
Phase I-II trial of mitoxantrone in acute leukemia: an interim report.
Topics: Acute Disease; Adult; Aged; Anthraquinones; Antineoplastic Agents; Digestive System; Drug Evaluation | 1985 |
Mitoxantrone in the treatment of relapsed and refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Child; Female; Humans | 1985 |
[Mitoxantrone--a new cytostatic agent].
Topics: Acute Disease; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Leukemia; Mi | 1985 |
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Bone Marrow; Child; D | 1985 |
Mitoxantrone in refractory acute leukemia in children: a phase I study.
Topics: Acute Disease; Adolescent; Alopecia; Anthraquinones; Antineoplastic Agents; Child; Child, Preschool; | 1985 |